Literature DB >> 25287736

Quantification of myocardial perfusion in clinical trials.

Mario Petretta1, Carmela Nappi, Alberto Cuocolo.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25287736     DOI： 10.1007/s12350-014-0003-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  29 in total

1.  The increasing role of quantification in clinical nuclear cardiology: the Emory approach.

Authors:  Ernest V Garcia; Tracy L Faber; C David Cooke; Russell D Folks; Ji Chen; Cesar Santana
Journal:  J Nucl Cardiol       Date:  2007-07       Impact factor: 5.952

2.  FDA approves pharmacologic stress agent.

Authors:  Cheryl A Thompson
Journal:  Am J Health Syst Pharm       Date:  2008-05-15       Impact factor: 2.637

3.  Clinical validation of SPECT attenuation correction using x-ray computed tomography-derived attenuation maps: multicenter clinical trial with angiographic correlation.

Authors:  Yasmin Masood; Yi-Hwa Liu; Gordon Depuey; Raymond Taillefer; Luis I Araujo; Steven Allen; Dominique Delbeke; Frank Anstett; Aharon Peretz; Mary-Jo Zito; Vera Tsatkin; Frans J Th Wackers
Journal:  J Nucl Cardiol       Date:  2005 Nov-Dec       Impact factor: 5.952

4.  Attenuation correction for myocardial perfusion SPECT imaging: still a controversial issue.

Authors:  Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-27       Impact factor: 9.236

5.  Improved coronary disease detection with quantitative attenuation-corrected Tl-201 images.

Authors:  Mathew Shotwell; Balkrishna M Singh; Charlotte Fortman; Brian D Bauman; Jennifer Lukes; Myron C Gerson
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

Review 6.  Gated SPECT myocardial perfusion imaging: the further improvements of an excellent tool.

Authors:  A Cuocolo; M Petretta; W Acampa; T De Falco
Journal:  Q J Nucl Med Mol Imaging       Date:  2010-04       Impact factor: 2.346

7.  Diagnostic performance of an expert system for the interpretation of myocardial perfusion SPECT studies.

Authors:  E V Garcia; C D Cooke; R D Folks; C A Santana; E G Krawczynska; L De Braal; N F Ezquerra
Journal:  J Nucl Med       Date:  2001-08       Impact factor: 10.057

Review 8.  Regadenoson: a focused update.

Authors:  Gopal Ghimire; Fadi G Hage; Jaekyeong Heo; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2013-04       Impact factor: 5.952

9.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

10.  Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials.

Authors:  John J Mahmarian; Leif E Peterson; Jiaqiong Xu; Manuel D Cerqueira; Ami E Iskandrian; Timothy M Bateman; Gregory S Thomas; Faisal Nabi
Journal:  J Nucl Cardiol       Date:  2014-10-07       Impact factor: 5.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.